SCHEMBL13102473

SCHEMBL13102473

O=C(Cc1ccc(F)cc1)Nn1c(C2CC2)nc2c(C3CC3)cccc2c1=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 8/20 0.40
ATM Q13315 1/20 0.40
TSHR P16473 4/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HTT P42858 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
NPSR1 Q6W5P4 1/20 0.37
SIGMAR1 Q99720 2/20 0.37
MAPK1 P28482 2/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KDM4E B2RXH2 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13102187 0.91 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1ATMTSHRPOLB
SCHEMBL13102453 0.91 ALDH1A1 (0.47) SMN1; SMN2ALDH1A1ATMTSHRLMNA
SCHEMBL13102268 0.89 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1TSHRPOLBLMNA
SCHEMBL13102472 0.88 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1POLBLMNAMEN1
SCHEMBL13102443 0.87 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1ATMTSHRPOLB
SCHEMBL13102088 0.86 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1ATMTSHRPOLB
SCHEMBL13102191 0.84 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1ATMTSHRLMNA
SCHEMBL13102202 0.81 PDE1C (0.42) SMN1; SMN2ALDH1A1ATMTSHRNPSR1
SCHEMBL13102286 0.81 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1ATMTSHRPOLB
SCHEMBL29830753 0.81 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1ATMTSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329713-B2 Fused ring heterocycles as potassium channel modulators ICAGEN INC. (US) 2012-12-11 US disclosed
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-10-28 US disclosed
US-7223768-B2 Fused ring heterocycles as potassium channel modulators ICAGEN, INC. (US) 2007-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNK17, KCNJ2, KCNJ1 SMN1; SMN2 253/4885ALDH1A1 2354/4885ATM 1284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.